Phase II study of Ccr-based dose-control of S-1 in the first-line chemotherapy of S-1/oxaliplatin (SOX) + bevacizumab regimen for advanced colorectal cancer

Authors :: Dai Manaka
T. Hattori
Ryo Kudo
Sayuri Konishi
Ryuta Nishitai
T. Ohta
H. Ann
K. Kawaguchi
Shinya Hamasu
Y. Nishikawa
Source :: Annals of Oncology. 28:v208
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
Bevacizumab
business.industry
Hematology
Oxaliplatin
Advanced colorectal cancer
Regimen
Internal medicine
medicine
First line chemotherapy
business
medicine.drug

Full Text Access

Tools